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genes, which affect antigen processing and 
presentation. It is therefore appropriate that 
such genes are usually inherited as a coordi-
nated set, given that both class I and class II 
gene products, many of which are encoded 
in the MHC, play on the same pool of T cell 
receptors.
Incidentally, many other regions of the 
genome also appear to be in linkage dis-
equilibrium, indicating that subtle epistatic 
effects at linked loci may be widespread. 
The order of genes in the human genome 
appears to us fairly random, but this may be 
illusory. New gene pairings are forged and 
subjected to selection as species are formed, 
and pairing of genes in different species 
may be advantageous rather than simply 
 fortuitous.
We may be beginning to understand how 
DR2a keeps the DR2b rottweiler in check 
and how obedience training of T cells by 
exposure to antigen may be beneficial. But 
how, in treating multiple sclerosis, do we 
throw the aggressive DR2b dog a juicy bone? 
Strategies designed to target and eliminate 
specific T cells might provide a lead.
1. Sospedra, M. & Martin, R. Annu. Rev. Immunol. 23, 
683–747 (2005).
2. Gregersen, J.W. et al. Nature doi: 10.1038/nature 
05133 
3. Lincoln, M.R. et al. Nat. Genet. 37, 1108–1112 
(2005).
4. Raymond, C.K. et al. Genome Res. 15, 1250–
1257(2005).
5. Trowsdale, J. Genome Biol. 3, 3 (2002).
Alzheimer disease: presenilin springs a leak
Sam Gandy, Mark K Doeven & Bert Poolman
Presenilins are thought to contribute to Alzheimer disease through a protein cleavage reaction that produces 
neurotoxic amyloid-β peptides. A new function for presenilins now comes to light—controlling the leakage of calcium 
out of the endoplasmic reticulum. Is this a serious challenge to the ‘amyloid hypothesis’ of Alzheimer disease?
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Several proteins are believed to be essential for 
the pathology of Alzheimer disease. Two of 
these proteins—presenilins—are involved in 
a cleavage reaction that generates key protein 
fragments, known collectively as amyloid-β 
peptides. According to this “amyloid hypothe-
sis”1, the clumping in the brain of one especially 
sticky form of amyloid-β peptide, amyloid-β42, 
is thought to define the final common pathway 
toward all forms of Alzheimer disease.
These molecular events have been recog-
nized for years, but now a twist emerges. In 
a recent issue of Cell, Tu et al.2 challenge the 
prevailing view of presenilin biology. They 
provide evidence that presenilins, in addi-
tion to their cleavage function, also form ion 
channels responsible for a normal trickle of 
calcium—known as the ‘calcium leak cur-
rent’—out of a storage depot in the endo-
plasmic reticulum and into the cytoplasm.
It’s not clear whether alterations in cal-
cium handling contribute to the pathology 
of the disease, although the new findings are 
in sync with previous studies hinting that 
this could be the case3,4. Also unclear is the 
relationship of altered calcium handling to 
the biology or pathology of amyloid-β. But 
the new findings should provoke a flurry of 
follow-on experiments evaluating whether 
or not the calcium leak data fit into the amy-
loid hypothesis.
Presenilin-1 and presenilin-2 are highly 
homologous, polytopic membrane proteins 
that were discovered about ten years ago 
through standard positional cloning strate-
gies aimed at identifying the genetic bases 
of the most common forms of early-onset 
familial Alzheimer disease1,5. Each pre-
senilin was later found to form a protein-
conducting pore, lined by the active site of 
the proteolytic activity that generates the C 
termini of amyloid-β peptides, an activity 
informally known as ‘γ-secretase’.
Cleverly, order is maintained between 
the secretase function of presenilin and its 
apparent role in calcium handling: it is the 
endoplasmic reticulum–localized, unpro-
cessed zymogen form of presenilin that acts 
as a calcium channel. The protease function 
of presenilin is only revealed in later com-
partments (such as the trans-Golgi network, 
endosome and plasma membrane) after the 
assembly of N- and C-terminal presenilin 
fragments together with three essential part-
ners (nicastrin, Aph1 and Pen2) necessary 
to form the minimal functional γ-secretase 
(Fig. 1) (refs. 1,5).
Dual-function pores conducting both 
proteins and ions are not unprecedented, 
as such activities were characterized in the 
early 1990s by Simon and Blobel6. This is 
the first time, however, that presenilins have 
been formally proposed to play roles in both 
protein processing and ion conductance. It 
is also true that membrane proteins have in 
the past been artifactually identified as ion 
channels when, in fact, their main physi-
ological function is the transport of some 
other substance (for example, the misiden-
tification of P-glycoprotein as a chloride 
channel7).
Tu et al.2 suggest that pathogenic missense 
mutations in the presenilin-1 gene cause 
loss of the normal endoplasmic reticulum 
calcium leak current, so that endoplasmic 
reticulum calcium levels are elevated in the 
resting state whereas cytosolic levels are 
normal or even low. Then, when cells are 
exposed to some stimulus that causes endo-
plasmic reticulum calcium channels to open, 
those excess endoplasmic reticulum cal-
cium stores are disgorged into the cytosol. 
Excessive cytosolic calcium is a well-known 
mediator of neuronal death, as has long been 
appreciated in studies of excitotoxicity.
The authors also examine a mutant pre-
senilin informally known as PS1Δ9 because 
it lacks the ninth exon. They report that 
this channel leaks calcium out of the endo-
plasmic reticulum to an excessive extent 
under basal conditions. PS1Δ9 is unusual 
in some other respects as well: it is active 
as a protease without being cleaved into N- 
and C-terminal fragments (NTF and CTF), 
and patients with this mutant protein have 
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8) that were nicknamed “monster plaques”8. 
In culture, PS1Δ9 generates an especially 
high ratio of amyloid-β42 to amyloid-β40, 
but this may be due to a deficiency in the 
generation of amyloid-β40 (ref. 9).
Calcium is no newcomer to the study 
of Alzheimer pathogenesis or of preseni-
lin action. In the mid-1980s, Gibson and 
Shelanski independently reported distur-
bances in calcium metabolism in fibroblasts 
cultured from biopsies of the skin from 
patients with Alzheimer disease, including 
(but not confined to) patients with prese-
nilin mutations3. The signal-transduction 
abnormalities in these skin cells seemed to 
be attributable to some poorly understood 
disturbance of calcium homeostasis, leading 
to the proposal of the “calcium hypothesis 
of Alzheimer disease”10. In the mid-1990s, 
several groups studied some of these same 
fibroblasts and found changes in amyloid-β 
in their conditioned media11,12.
Meanwhile, a substantial literature has 
accumulated over the past decade indicat-
ing a link between presenilins and calcium. 
More than 100 papers from six separate 
laboratories4 link presenilins to some role 
in calcium homeostasis. Clearly, the Tu et al. 
claim that presenilins direct most calcium 
leak current is cause for reflection.
Assuming that the results are confirmed, 
one question has the greatest clinical signifi-
cance: which phenomenon is more impor-
tant for pathology, calcium or amyloid-β? 
(Fig. 2). Conceivably, disturbed endoplas-
mic reticulum calcium leakage and aber-
rant amyloid-β metabolism might be tightly 
linked.
Is accurate γ-cleavage required for proper 
endoplasmic reticulum calcium leakage? 
This seems unlikely, because Oh and Turner 
were unable to demonstrate any alterations 
in intracellular calcium stores after phar-
macological inhibition of γ-secretase func-
tion13. Alternatively, can calcium control 
amyloid-β metabolism? Here the answer is 
clearly “yes.”
Calcium perturbation has been shown to 
dynamically modulate amyloid-β release, 
in both positive and negative directions4,14. 
Perhaps abnormal endoplasmic reticulum 
calcium leakage sets up a cytoplasmic sig-
nal transduction environment that enhances 
amyloid-β release. Normally, one important 
source of cytoplasmic calcium in neurons is 
its entrance through voltage-gated calcium 
channels after electrical depolarization. 
Because neurotransmission and depolar-
ization regulate physiological amyloid-β 
release5,14, one can easily imagine that 
pathological increases in cytoplasmic cal-
cium could do the same.
An extensive clinicopathological and bio-
chemical correlation study of mutant prese-
nilin phenotypes could help resolve whether 
calcium or amyloid-β is more important 
for the pathogenesis of Alzheimer disease. 
Although over 100 pathogenic mutations 
in the presenilins have been identified, rela-
tively few of them have been studied in detail. 
Abnormalities in amyloid-β42/amyloid-β40 
ratios associated with presenilin mutations 
are barely detectable in some cases, and in 
at least one family, a mutant presenilin inca-
pable of generating amyloid-β can apparently 
cause familial Alzheimer disease8.
In contrast (and also surprisingly), a few 
families with hereditary dementia and prese-
nilin mutations have recently been reported 
to be entirely devoid of amyloid-β patho-
logy15. The presence of presenilin mutations, 
familial dementia and an apparent amyloid-β 
–independent neuropathological pheno-
type may incriminate calcium and exculpate 
amyloid-β� in the pathophysiology of at least 
some mutant presenilin disease.
Nonetheless, when formulating a global 
definition for Alzheimer disease, one must 
keep in mind that primary endoplasmic 
reticulum calcium leak failure is clearly not 
necessary to cause Alzheimer disease. The 
first pathogenic mutations discovered to 
cause amyloid-β pathology were found not 
in presenilins but in the amyloid precursor 
protein1,5. These mutations are localized 
within or around the amyloid-β domain, 
and they are sufficient to cause the com-
plete clinical and pathological picture of 
Alzheimer disease. Notably, however, extra-
cellular amyloid-β oligomers can apparently 
induce cytoplasmic calcium disturbances16. 
Perhaps particular patterns of calcium dys-
regulation and amyloid-β mismetabolism 
set up a vicious cycle in which toxicity from 
each provokes higher levels of the other.
Another question raised by the data of Tu 
et al. is whether the newly described endo-
plasmic reticulum calcium leak dysfunction 
can provide a parsimonious explanation 
for all the reported aberrancies in calcium 
metabolism attributed to presenilin muta-
tions4. The answer here is, “No, at least not 
obviously.” Fingering presenilin as an endo-
plasmic reticulum calcium leak channel does 
not immediately bring clarity to the existing 
literature on presenilin and calcium.
In the final analysis, clinical trials will be 
required to resolve the most critical issue—
that is, whether calcium handling or amy-
loid-β is the better therapeutic opportunity 
in common, so-called ‘sporadic’ forms of 
Alzheimer disease. Perhaps we will need to 
target both to arrest the disease completely.
To date, the experience with Alzheimer 
therapeutic trials aimed at calcium has 
been limited to compounds that block L-
type voltage-dependent calcium channels. 
Figure 1  Calcium, amyloid-β,  
presenilin and Alzheimer 
disease. Presenilin holoproteins 
modulate calcium leakage from 
the endoplasmic reticulum (ER), 
whereas their cleaved derivatives 
(PS1 NTF for presenilin N-terminal 
fragment; CTF for C-terminal 
fragment) assemble with partners 
(Aph1, Pen2, and nicastrin (Nic)) 
to form the functional protease 
complex (γ-secretase), which is 
concentrated in the trans-Golgi 
network (TGN) and endocytic 
system. γ-Secretase cuts β-cleaved 
C-terminal fragments (βCTFs) of the 
amyloid precursor protein (APP), 
releasing amyloid-β peptide (Aβ), 
indicated in orange. Aβ is initially 
localized in the TGN lumen (dark 
blue), endosome lumen (dark blue) 
or both, but is rapidly released from 
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These drugs were apparently ineffective, 
but perhaps other calcium-modulating 
compounds, specifically targeting endo-
plasmic reticulum pools of calcium, would 
yield a more favorable outcome. In light of 
the fresh insights from Tu et al., the good 
news is that we already know a great deal 
about calcium pharmacology—enough to 
give us a substantial head start if, indeed, 
the “calcium hypothesis of Alzheimer’s”10 
is back to stay.
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Figure 2  Potential steps leading from familial Alzheimer mutations (APP mutations, PS1 mutations) to 
neurotoxicity and neurodegeneration, via either Aβ-dependent (left) or Aβ-independent (right) pathways. 
Proximate mediators of toxicity (Aβ oligomers, calcium) are connected to the cartoon neuron using dashed 
arrows.
Alzheimer disease: BACE1 branches out
An enzyme that helps generate clumps of amyloid-β in the brains of 
people with Alzheimer disease also has a role in myelinating axons, 
according to a study in Science (doi: 10.1126/science.1132341). The 
findings sound a cautionary note for ongoing efforts to develop drugs to 
inactivate this enzyme.
The enzyme, BACE1 (beta-site amyloid precursor protein–cleaving 
enzyme 1), is required to cleave amyloid-β from a larger precursor.  
(After BACE1-mediated cleavage, the presenilin-containing complex  
γ-secretase makes the final cleavage, liberating amyloid-β.)
Michael Willem et al. found that BACE1 seems to be required for 
processing a signal, the EGF-like factor neuregulin 1,that activates 
receptors on Schwann cells. Activation of these receptors is required for 
myelination.
One observation supporting this hypothesis was that animals deficient 
in BACE-1 had myelin defects in the peripheral nerves. Shown is a 
cross-section of the sciatic nerve of an 8-day-old BACE1-deficient 
mouse; myelin sheath in black.  The myelin is thinner than in wild-type 
mice and some axons lack myelin altogether.
Peripheral nerve myelination occurs early in life, so it is unclear how 
BACE1 inhibition might affect older animals. Whether BACE1 also has a 
role in myelination of the central nervous system is also unclear.
—Charlotte Schubert
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